Inhibition of GST-pi nuclear transfer increases mantle cell lymphoma sensitivity to cisplatin, cytarabine, gemcitabine, bortezomib and doxorubicin

Anticancer Research

Volumn 30, Issue 10, 2010, Pages 3951-3957

  Rolland, D ^a,b   Raharijaona, M ^c,d   Barbarat, A ^e   Houlgatte, R ^c,d   Thieblemont, Catherine ^c,f,g  

^a GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

^d UNIVERSITÉ DE NANTES   (France)

^e UNIVERSITÉ LYON 1   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Anticancer agents; Class pi glutathione S transferase; Inhibition; Mantle cell lymphoma; Nuclear transfer

Indexed keywords

AGARICUS BISPORUS LECTIN; BORTEZOMIB; CISPLATIN; CISPLATINE; CYTARABINE; DOXORUBICIN; GEMCITABINE; GLUTATHIONE TRANSFERASE P1; LECTIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LYMPHOMA CELL; LYMPHOMA CELL LINE; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CISPLATIN; CYTARABINE; DEOXYCYTIDINE; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; GLUTATHIONE S-TRANSFERASE PI; HUMANS; LECTINS; LYMPHOMA, MANTLE-CELL; PYRAZINES;

EID: 78650249967     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. de Boer CJ, van Krieken JH, Kluin-Nelemans HC, Kluin PM and Schuuring E: Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma. Oncogene 10: 1833-1840, 1995.
2. Li JY, Gaillard F, Moreau A, Harousseau JL, Laboisse C, Milpied N, Bataille R and Avet-Loiseau H: Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization. Am J Pathol 154: 1449-1452, 1999.
3. Rosenberg CL, Wong E, Petty EM, Bale AE, Tsujimoto Y, Harris NL and Arnold A: PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci USA 88: 9638-9642, 1991.
4. Lefrere F, Delmer A, Suzan F, Levy V, Belanger C, Djabarri M, Arnulf B, Damaj G, Maillard N, Ribrag V, Janvier M, Sebban C, Casasnovas RO, Bouabdallah R, Dreyfus F, Verkarre V, Delabesse E, Valensi F, McIntyre E, Brousse N, Varet B and Hermine O: Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 16: 587-593, 2002.
5. Haas R, Brittinger G, Meusers P, Murea S, Goldschmidt H, Wannenmacher M and Hunstein W: Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. Leukemia 10: 1975-1979, 1996.
6. Blay JY, Sebban C, Surbiguet C, Ouachee M, Philip I, Philip T and Biron P: High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin's lymphomas: a single center experience on 18 patients. Bone Marrow Transplant 21: 51-54, 1998.
7. Campo E, Raffeld M and Jaffe ES: Mantle-cell lymphoma. Semin Hematol 36: 115-127, 1999.
8. Foran JM, Cunningham D, Coiffier B, Solal-Celigny P, Reyes F, Ghielmini M, Johnson PW, Gisselbrecht C, Bradburn M, Matthews J and Lister TA: Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol. 11(Suppl 1): 117-121, 2000.
9. Thieblemont C, Nasser V, Felman P, Leroy K, Gazzo S, Callet-Bauchu E, Loriod B, Granjeaud S, Gaulard P, Haioun C, Traverse-Glehen A, Baseggio L, Bertucci F, Birnbaum D, Magrangeas F, Minvielle S, Avet-Loiseau H, Salles G, Coiffier B, Berger F and Houlgatte R: Small lymphocytic lymphoma, marginal zone B-cell lymphoma and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood 103: 2727-2737, 2004.
10. Bennaceur-Griscelli A, Bosq J, Koscielny S, Lefrere F, Turhan A, Brousse N, Hermine O and Ribrag V: High level of glutathione-S-transferase pi expression in mantle cell lymphomas. Clin Cancer Res 10: 3029-3034, 2004.
11. Mannervik B, Alin P, Guthenberg C, Jensson H, Tahir MK, Warholm M and Jornvall H: Identification of three classes of cytosolic glutathione transferase common to several mammalian species: correlation between structural data and enzymatic properties. Proc Natl Acad Sci USA 82: 7202-7206, 1985.
12. Sundberg K, Widersten M, Seidel A, Mannervik B and Jernstrom B: Glutathione conjugation of bay- and fjord-region diol epoxides of polycyclic aromatic hydrocarbons by glutathione transferases M1-1 and P1-1. Chem Res Toxicol 10: 1221-1227, 1997.
13. Ribrag V, Koscielny S, Carpiuc I, Cebotaru C, Vande Walle H, Talbot M, Fenaux P and Bosq J: Prognostic value of GST-pi expression in diffuse large B-cell lymphomas. Leukemia 17: 972-977, 2003.
14. Whelan RD, Waring CJ, Wolf CR, Hayes JD, Hosking LK and Hill BT: Over-expression of P-glycoprotein and glutathione S-transferase pi in MCF-7 cells selected for vincristine resistance in vitro. Int J Cancer 52: 241-246, 1992.
15. O'Brien ML and Tew KD: Glutathione and related enzymes in multidrug resistance. Eur J Cancer 32A: 967-978, 1996.
16. Berhane K, Widersten M, Engstrom A, Kozarich JW and Mannervik B: Detoxication of base propenals and other alpha, beta-unsaturated aldehyde products of radical reactions and lipid peroxidation by human glutathione transferases. Proc Natl Acad Sci USA 91: 1480-1484, 1994.
17. Huang G, Mills L and Worth LL: Expression of human glutathione S-transferase P1 mediates the chemosensitivity of osteosarcoma cells. Mol Cancer Ther 6: 1610-1619, 2007.
18. Tew KD, Bomber AM and Hoffman SJ: Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines. Cancer Res 48: 3622-3625, 1988.
19. Hansson J, Berhane K, Castro VM, Jungnelius U, Mannervik B and Ringborg U: Sensitization of human melanoma cells to the cytotoxic effect of melphalan by the glutathione transferase inhibitor ethacrynic acid. Cancer Res 51: 94-98, 1991.
20. Ban N, Takahashi Y, Takayama T, Kura T, Katahira T, Sakamaki S and Niitsu Y: Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan and etoposide. Cancer Res 56: 3577-3582, 1996.
21. Shiratori Y, Soma Y, Maruyama H, Sato S, Takano A and Sato K: Immunohistochemical detection of the placental form of glutathione S-transferase in dysplastic and neoplastic human uterine cervix lesions. Cancer Res 47: 6806-6809, 1987.
22. Ali-Osman F, Brunner JM, Kutluk TM and Hess K: Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. Clin Cancer Res 3: 2253-2261, 1997.
23. Goto S, Kamada K, Soh Y, Ihara Y and Kondo T: Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs. Jpn J Cancer Res 93: 1047-1056, 2002.
24. Goto S, Ihara Y, Urata Y, Izumi S, Abe K, Koji T and Kondo T: Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione S-transferase pi. FASEB J 15: 2702-2714, 2001.
25. Yu LG, Fernig DG, White MR, Spiller DG, Appleton P, Evans RC, Grierson I, Smith JA, Davies H, Gerasimenko OV, Petersen OH, Milton JD and Rhodes JM: Edible mushroom (Agaricus bisporus) lectin, which reversibly inhibits epithelial cell proliferation, blocks nuclear localization sequence-dependent nuclear protein import. J Biol Chem 274: 4890-4899, 1999.
26. Witzig TE: Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 23: 6409-6414, 2005.
27. D'Arpa P and Liu LF: Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 989: 163-177, 1989.
28. Wang D and Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320, 2005.
29. Matsuda A and Sasaki T: Antitumor activity of sugar-modified cytosine nucleosides. Cancer Sci 95: 105-111, 2004. (Pubitemid 38404309)
30. Milano A, Iaffaioli RV and Caponigro F: The proteasome: a worthwhile target for the treatment of solid tumours? Eur J Cancer 43: 1125-1133, 2007.
31. Serafino A, Sinibaldi-Vallebona P, Gaudiano G, Koch TH, Rasi G, Garaci E and Ravagnan G: Cytoplasmic localization of anthracycline antitumor drugs conjugated with reduced glutathione: a possible correlation with multidrug resistance mechanisms. Anticancer Res 18: 1159-1166, 1998.
32. Müller I, Niethammer D and Bruchelt G: Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity. Int J Mol Med 1: 491-494, 1998.
33. Jing XB, Cai XB, Hu H, Chen SZ, Chen BM and Cai JY: Reactive oxygen species and mitochondrial membrane potential are modulated during CDDP-induced apoptosis in EC-109 cells. Biochem Cell Biol 85: 265-271, 2007.
34. Hedley DW and McCulloch EA: Generation of reactive oxygen intermediates after treatment of blasts of acute myeloblastic leukemia with cytosine arabinoside: role of bcl-2. Leukemia 10: 1143-1149, 1996.
35. Ling YH, Liebes L, Zou Y and Perez-Soler R: Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 278: 33714-33723, 2003.
36. Miller EC and Miller JA: Mechanisms of chemical carcinogenesis. Cancer 47: 1055-1064, 1981.
37. Inouye S: Site-specific cleavage of double-strand DNA by hydroperoxide of linoleic acid. FEBS Lett 172: 231-234, 1984.
38. Wang MY and Liehr JG: Lipid hydroperoxide-induced endogenous DNA adducts in hamsters: possible mechanism of lipid hydroperoxide-mediated carcinogenesis. Arch Biochem Biophys 316: 38-46, 1995.
39. Kamada K, Goto S, Okunaga T, Ihara Y, Tsuji K, Kawai Y, Uchida K, Osawa T, Matsuo T, Nagata I and Kondo T: Nuclear glutathione S-transferase pi prevents apoptosis by reducing the oxidative stress-induced formation of exocyclic DNA products. Free Radie Biol Med 37: 1875-1884, 2004.
40. Rosario LA, O'Brien ML, Henderson CJ, Wolf CR and Tew KD: Cellular response to a glutathione S-transferase P1-1 activated prodrug. Mol Pharmacol 58: 167-174, 2000.
41. Sequist LV, Fidias PM, Temel JS, Kolevska T, Rabin MS, Boccia RV, Burris HA, Belt RJ, Huberman MS, Melnyk O, Mills GM, Englund CW, Caldwell DC, Keck JG, Meng L, Jones M, Brown GL, Edelman MJ and Lynch TJ: Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer. J Thorac Oncol 4: 1389-1396, 2009.